Advancing Precision Medicine for Neuro-Oncology Patients: Q&A with David Solomon, MD, PhD

International Nurses Day 2022: A Voice to Lead - Invest in Nursing and Respect Rights to Secure Global Health

Every year the International Council of Nurses (ICN) commemorates International Nurses Day on May 12th, the birthday of Florence Nightingale. This year’s theme: Nurses: A Voice to Lead - Invest in nursing and respect rights to secure global health is a multifaceted call to allocate resources to

Joining Forces to Fight Pancreatic Cancer

Although it doesn’t tend to get as much media attention as other diseases, pancreatic cancer is the third-leading cause of cancer-related deaths and is on track to become the second most fatal cancer by 2030. It is one of the few cancers that’s becoming more common, and those who are affected have a

Renowned Hematology-Oncology Specialist to Lead UCSF Health’s Hematology-Oncology Program

UC San Francisco’s Division of Hematology-Oncology is welcoming Krishna Komanduri, MD, as division chief of Hematology-Oncology at UCSF Health. Komanduri is an international leader in the fields of hematology-oncology, transplantation, and cellular immunotherapy. He will start at UCSF on July 1. In

Nutrition Counseling Program Turns 20!

This January, the UCSF Cancer Center’s Outpatient Nutrition Counseling program celebrated its 20th anniversary. This landmark anniversary is a great opportunity to look back at the origins of the Nutrition Counseling Program which presently consists of Greta Macaire, RD, MA; Anna Hom, RD, MS; Neha

Seven Cancer Research Projects Funded in Fall 2021 RAP Cycle

Seven investigators and teams were awarded grants in support of cancer research projects in the fall 2021 cycle of the UCSF Resource Allocation Program (RAP). Funded by various agencies across UCSF, the awards span a range of topics from exploring imaging techniques to piloting screening

Treating Tough Tumors by Exploiting Their Iron ‘Addiction’

Researchers at UC San Francisco have successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths. Taking advantage of what they discovered to be the cancer cells’